Study Finds Gabapentinoids Unlikely to Directly Increase Self-Harm Risk, Urges Patient Monitoring

A large UK study published in The BMJ has found that gabapentinoids-a class of drugs including gabapentin and pregabalin-are not directly linked to an elevated risk of self-harm. However, researchers emphasize the critical need for close patient monitoring before, during, and after treatment, particularly in the high-risk weeks following discontinuation.

Key Findings

• Pre-Treatment Risk Spike: Self-harm rates were 69% higher in the 90 days before starting gabapentinoids (16.8 cases per 100 person-years), suggesting patients may already be vulnerable when prescribed these medications.

• Post-Treatment Surge: Rates spiked to 29.6 per 100 person-years in the two weeks after stopping treatment, indicating heightened risk during withdrawal or transition periods.

• Treatment Period: Self-harm risk declined during active treatment, aligning with baseline levels observed outside critical windows.

Study Design
Researchers analyzed 10,002 UK patients (average age 39; 67% female) with hospital-recorded self-harm episodes between 2000–2020. By comparing individuals’ self-harm rates across four periods-pre-treatment, active treatment, post-treatment, and baseline-the study minimized confounding factors like genetics and environment.

Why It Matters
Gabapentinoids are widely prescribed for nerve pain, epilepsy, and anxiety, but prior studies raised concerns about psychiatric side effects. This research clarifies that while the drugs themselves may not directly cause self-harm, vulnerable patients require structured care, especially during transitions.

Expert Recommendations
The authors urge clinicians to:

1. Monitor closely during initiation and discontinuation.

2. Assess underlying risks in patients prescribed gabapentinoids for pain or mental health conditions.

3. Prioritize follow-ups within two weeks of stopping treatment.

Limitations

• The study focused on severe self-harm cases requiring hospitalization.

• Prescription data excluded non-GP sources (e.g., specialists).

• Small subgroup sizes may affect certain analyses.

Conclusion
“These findings underscore the necessity for close patient monitoring throughout the gabapentinoid treatment journey,” the researchers wrote. An accompanying editorial stressed the importance of routine follow-ups, particularly after discontinuation.

Journal Reference:
Association of gabapentinoid treatment and the risk of self-harm: self-controlled, population based case series, The BMJ (2025). DOI: 10.1136/bmj-2024-081627

Disclaimer: This article summarizes findings from a peer-reviewed study. Individual patient experiences may vary, and decisions regarding medication use should always involve consultation with a qualified healthcare provider. The study’s observational design cannot prove causation, and results may not generalize to all populations. For personalized advice, seek professional medical guidance.

Source: Medical Xpress, 30 April 2025 (adapted).